Zhejiang Huode Bioengineering

Hode Bio is a clinical-stage biotechnology company focused on developing induced pluripotent stem cell (iPSC) derived cell therapies for central nervous system (CNS) disorders. The company utilizes a proprietary platform for the highly efficient and stable differentiation of iPSCs into clinical-grade neural cells. Its lead product, hNPC01, is a neural progenitor cell therapy currently being evaluated in Phase 1/2 clinical trials for ischemic stroke and spinal cord injury. Headquartered in Hangzhou, China, Hode Bio was founded by scientists from Johns Hopkins University and is supported by prominent venture capital firms. The company's mission is to provide innovative regenerative treatments for patients suffering from debilitating neurological conditions.